SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series July category listing 07/11

20110184157 - Methods of producing bacterial alginates: Methods for mass producing bacterial alginate, bacterial cultures for producing alginate, and pharmaceutical compositions containing bacterial alginate are contemplated.... Agent: Marshall University Research Corporation

20110184158 - Hydrates of erythromycin salts, preparation and use thereof: The present invention relates to a macrolide derivative as well as preparation and use thereof. The macrolide derivative of the present invention, i.e., a hydrate of erythromycin salts, has a molecular formula of C37H67NO13.A.nH2O, n=1.0-11.0, in which A is an organic acid or an organic acids, selected from lactobionic acid,... Agent:

20110184159 - Process for production of radiopharmaceuticals: The present invention relates to novel processes for the production of F-18 labeled radiotracers for Positron Emission Tomography (PET). The invention also comprises radiopharmaceutical kits using these processes.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110184160 - Nucleic acid molecule encoding consensus influenza a hemagglutinin h1: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided.... Agent:

20110184161 - Use of microarrays for genomic representation selection: The present invention provides novel methods for reducing the complexity of a genomic sample for further analysis such as direct DNA sequencing, resequencing or SNP calling. The methods use pre-selected immobilized oligonucleotide probes to capture target nucleic acid molecules from a sample containing denatured, fragmented genomic nucleic acid. The disclosed... Agent:

20110184162 - Method for rapid isolation of rna and a kit thereof: The present invention relates to a method for rapid isolation of RNA. More particularly, it relates to a method for isolation of RNA using two-solution system. The present invention also relates to a RNA isolation kit.... Agent: Council Of Scientific And Industrial Research

20110184163 - Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis: Nucleotide triphosphate probes containing a molecular and/or atomic tag on a a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents... Agent: Life Technologies Corporation

20110184164 - Pathogen-resistant fabrics: A pathogen-resistant fabric comprising one or more photocatalysts capable of generating singlet oxygen from ambient air. The pathogen-resistant fabric may optionally include one or more singlet oxygen traps.... Agent:

20110184165 - Aggregate zeolitic absorbents, their method of preparation and their uses: p

20110178281 - Photocleavable linker methods and compositions: Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110178282 - Methods and compositions for cancer therapy using a novel adenovirus: The invention comprises a novel virus that can kill mammalian cancer cells efficiently. The virus produces a novel protein that converts two non-toxic prodrugs into potent chemotherapeutic agents. These chemotherapeutic agents are produced locally and help the virus kill the cancer cells as well as sensitize them to radiation. In... Agent:

20110178283 - Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes: Sequences that can be used in the context of controlled gene regulation are provided. In one aspect, at least one sequence comprising at least one of one or more sequences having SEQ ID NO: 1 through SEQ ID NO: 747,326 is provided. One or more of the provided sequences may... Agent: International Business Machines Corporation

20110178285 - Methods and compositions for processing chemical reactions: Disclosed herein are compositions, methods and systems for the processing of chemical reactions, such as the synthesis of polymers.... Agent:

20110178284 - Novel protective group for synthesis of rna and derivative: A protective group represented by the following general formula (I) (the oxygen atom attached with * represents oxygen atom of 2′-hydroxyl group of a ribonucleoside, a ribonucleotide or a derivative thereof; R1 and R2 both represent hydrogen atom, or represent a halogen atom, a C1-6 alkyl group, or a C1-6... Agent: Chiralgen, Ltd.

20110178286 - Consumable analytical plasticware comprising high-solubility plastics: Consumable analytical plasticware comprising polymers having solubility parameters of about 9.5 (cal/cm3)1/2 or greater are described herein. Also disclosed are methods of using the consumable analytical plasticware, for example, to increase the yields of biomolecules such as nucleic acids from biological samples.... Agent:

20110178287 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.... Agent: Cerulean Pharma Inc.

20110178288 - Process for the production of maltodextrins and maltodextrins: There is disclosed a process for preparing liquid maltodextrin having a D.E. of about 5 to less than about 20. Also disclosed are liquid maltodextrins having a D.E. of about 9 to about 15.... Agent: Cargill, Incorporated

20110178289 - Construction of new variants of dextransucrase dsr-s by genetic engineering: The present invention relates to a recombinant process for the production of truncated or mutated dextransucrases while conserving the enzymatic activity or their specificity in the synthesis of the α-1,6 bonds. The present invention relates to nucleic acid sequences of truncated or mutated dextransucrases, vectors containing the nucleic acid sequences... Agent: Institut National Des Sciences Appliquees De Toulouse

20110178290 - Process for the production of hcl gas from chloride salts and for the production of carbohydrates: A process for the co-production of gaseous HCl and a salt product comprising a cation and an anion, which process comprises the steps of a. providing an aqueous solution comprising protons, chloride anions, and cations and anions of the salt product, b. bringing the solution into contact with a substantially... Agent: Hcl Cleantech Ltd.

20110172402 - Crystallizing method of erythromycin: The present invention provides an erythromycin crystallizing method, which comprises using dichloromethane containing solvent as a preparation solvent, and the dichloromethane solution of erythromycin received was gradiently cooled from high temperature down to low temperature, and thus making erythromycin crystallize. According to the method of the present invention, the content... Agent: Sunshine Lake Pharma Co., Ltd

20110172405 - Method for small rna isolation: This invention relates to a simple and rapid method for the extraction and purification of small RNA from a sample solution. Accordingly, a sample is first mixed with an organic solvent to form a mixture containing the solvent. The mixture is applied to a first mineral support for large RNA... Agent: Ge Healthcare Bio-sciences Corp.

20110172403 - Microfluidic device including purification column with excess diluent and method: Methods, apparatus, and a system are provided for processing a sample in a fluidic device. The device can include a purification column, an entrance opening to the purification column, an output reservoir, a fluid communication between the purification column and the output reservoir, and an openable and recloseable valve capable... Agent: Life Technologies Corporation

20110172404 - Self-assembly of nanoparticles through nuclei acid engineering: A self-assembly nanodevice formed through nucleic acid engineering is disclosed. The nanodevice may include an array of nanoparticles. The nanodevice may further include a substrate that supports the array of nanoparticles. Each of the nanoparticles may be coordinated with a plurality of nucleic acids that are substantially free of Watson-Crick... Agent: Cornell University

20110172406 - Molecular structure of rhd negative: The present invention relates to a nucleic acid molecular structure representing the Rhesus genes locus comprising the RHD, SMP1 and RHCE genes and/or the Rhesus box(es), preferably the hybrid Rhesus box, the upstream Rhesus bar and/or the downstream Rhesus box. Furthermore, the invention relates to a process for the specific... Agent: Drk-blutspendedienst Baden-wurttermberg-hessen Gemeinnutzige Gmbh

20110172407 - Phenotypic and genotypic differences of mva strains: The present invention provides kits and methods to screen viral nucleic acids for a profile of genetic deletions and mutations, optionally in combination with one or more assays for viral replication and/or attenuation capacity.... Agent:

20110172409 - Method for nucleic acid isolation by solid phase reversible binding of nucleic acids: The invention includes a method for separating polynucleotides, such as DNA, RNA and PNA, from a solution containing polynucleotides by reversibly and non-specifically binding the polynucleotides to a solid surface having a functional amide group-coated surface. The materials containing a solid surface can be in the form of microparticles, fibers,... Agent:

20110172408 - Recovery of nucleic acids from magnetic glass particles: The present invention is a method of separating nucleic acids using a solid phase capable of binding nucleic acids, such as magnetic glass particles, where binding of nucleic acids to the solid phase is enhanced by the presence of an ethylene-amine compound. The invention further includes a reaction mixture for... Agent: Roche Molecular Systems, Inc.

20110172410 - Antiviral nucleosides: 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.... Agent: Medivir Ab

20110172411 - Process for separation of ca- or mg-sulfite spent liquor to yield crystalline xylose: A process for the separation of a xylose-containing, lignosulphonate-containing Ca-sulfite spent liquor is provided. The process comprises a first step of: (A) chromatographic separation of the Ca- or Mg-sulfite spent liquor using a single pass through a batch-type long resin bed chromatography column having a strong acid cation exchange resin... Agent: Danisco A/s

20110166334 - Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.... Agent: Isis Pharmaceuticals,inc.

20110166335 - Xenorhabdus sp. genome sequences and uses thereof: The present invention relates to nucleic acid sequences from Xenorhabdus and, in particular, to genomic DNA sequences, and to the insecticidal Xenorhabdus strain Xs85816. The invention encompasses nucleic acid molecules present in non-coding regions as well as nucleic acid molecules that encode proteins, fragments of proteins, tRNA's, fragments of tRNA's,... Agent:

20110166336 - Identification of new small rnas and orfs of e. coli as mediators of cell and intercell regulation: The invention relates to new small RNAs and ORFs of E. coli as mediators of cell and intercell regulation.... Agent: United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services

20110166337 - Maize promoter p67 and methods of use: A promoter isolated from Zea mays provides a high level of specificity for expression in developing pollen, particularly at the mid-uninucleate stage. Compositions and methods of use are disclosed.... Agent: Pioneer Hi-bred International, Inc.

20110166338 - Reagent, chaotropic agent, and reagent kit for and applications of isolating nucleic acid by use of magnetic cellulose material: Disclosed are a chaotropic agent; a reagent including a chaotropic agent and a lithium salt; a reagent kit including a chaotropic agent; a chaotropic agent, a reagent, a reagent kit, and a method for isolating a nucleic acid by use of a magnetic cellulose material; a method for binding a... Agent:

20110166339 - Crystalline carbohydrate derivative: α-Lactosamine hydrochloride, substantially free of β-lactosamine hydrochloride; a method of preparing α-lactosamine hydrochloride monohydrate from an anomeric mixture of lactosamine hydrochloride, including: preparing a solution including the anomeric mixture of lactosamine hydrochloride, water and at least one water-miscible organic solvent at a temperature of 0-100° C., and cooling the solution... Agent: Glycom A/s

20110166340 - Process for adjusting degree of acetyl substitution of cellulose acetate: A process for adjusting an intermolecular or intramolecular degree of acetyl substitution of cellulose acetate is disclosed. The process comprises ripening cellulose acetate in the presence of a catalyst, an acetyl donor, and water or an alcohol. The amount of water and the alcohol is in the range of 0.1... Agent:

20110166341 - Glyoxal free purified cationic polygalactomannan: A glyoxal and boron free purified cationic polygalactomannan may be prepared by reacting a polygalactomannan flour, a nonionically derivatized polygalactomannan flour, or a mixture thereof, with a cationising reagent, adjusting the pH to be from about 4 to about 6; cross-linking the cationic with glyoxal, and filtering and water washing... Agent: Lamberti Spa